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Abstract: Congenital microcephaly is the clinical presentation of significantly reduced head circumfer-
ence at birth. It manifests as both non-syndromic—microcephaly primary hereditary (MCPH)—and
syndromic forms and shows considerable inter- and intrafamilial variability. It has been hypothesized
that additional genetic variants may be responsible for this variability, but data are sparse. We have
conducted deep phenotyping and genotyping of five Pakistani multiplex families with either MCPH
(n = 3) or Seckel syndrome (n = 2). In addition to homozygous causal variants in ASPM or CENPJ, we
discovered additional heterozygous modifier variants in WDR62, CEP63, RAD50 and PCNT—genes
already known to be associated with neurological disorders. MCPH patients carrying an additional
heterozygous modifier variant showed more severe phenotypic features. Likewise, the phenotype of
Seckel syndrome caused by a novel CENPJ variant was aggravated to microcephalic osteodysplastic
primordial dwarfism type II (MOPDII) in conjunction with an additional PCNT variant. We show
that the CENPJ missense variant impairs splicing and decreases protein expression. We also observed
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centrosome amplification errors in patient cells, which were twofold higher in MOPDII as compared
to Seckel cells. Taken together, these observations advocate for consideration of additional variants in
related genes for their role in modifying the expressivity of the phenotype and need to be considered
in genetic counseling and risk assessment.
Keywords: MCPH; Seckel syndrome; modifier alleles; primordial dwarfism; impaired splicing;
supernumerary centrosomes
1. Introduction
Microcephaly is characterized by a reduced occipitofrontal circumference (OFC) of
<−3 standard deviation (SD) based on the age-, gender- and ethnicity-matched mean.
It affects 2–3% of the population globally [1] and manifests in cognitive or neurological
dysfunction that requires constant medical care. Microcephaly may be congenital (primary)
or acquired postnatally (secondary). Primary microcephaly occurs as isolated (without any
further features), non-syndromic (with neurological or psychiatric features but without
further major morphologic or functional anomalies) and syndromic (in combination with
brain malformations and/or other major morphological or functional abnormalities), such
as Cohen syndrome (MIM #216550), Cornelia de Lange syndrome (MIM #122470), Nijmegen
breakage syndrome (MIM #251260), Smith–Lemli–Opitz syndrome and many more [2].
Primary non-syndromic microcephaly makes a distinct subclass, termed as micro-
cephaly primary hereditary (MCPH (MIM #251200)) or autosomal recessive primary mi-
crocephaly. It is known to be associated with 28 different genes, the latest being RRP7A,
which encodes a novel component of ribosome biogenesis and was identified in a large
Pakistani family [3–5]. MCPH has been clinically defined as a disorder of prenatal onset,
non-progressive intellectual disability (ID), lack of major brain malformations or major
birth defect in a non-central nervous system organ [6]. On the contrary, Seckel syndrome
(MIM #210600 for SCKL1) is an allelic disorder of MCPH (shared genetic architecture)
that features a short stature and characteristic facies with a prominent nose in addition to
congenital microcephaly and ID. Ten genes have been reported for Seckel syndrome so far,
and four of them (CENPJ, CEP152, CDK5RAP2 and CEP63) are also involved in MCPH [7].
Microcephalic osteodysplastic primordial dwarfism (MOPD) II manifests features overlap-
ping with Seckel syndrome but these patients feature a characteristic skeletal dysplasia, too.
MOPD is known to be caused by homozygous loss-of-function mutations in a particular
gene, PCNT [8]. For classical MCPH and Seckel syndrome, both intra- and interfamilial
clinical variability (even for the same variant) have been frequently observed [9,10], which
makes it difficult to infer a genotype–phenotype correlation. Although other genomic
loci had been considered to contribute to the variability, they were less tangible through
traditional genetic approaches.
With the latest trends and down pricing of next-generation sequencing technologies,
it is now possible to identify variants in other genes that are not pathogenic on their
own but nevertheless influence the phenotypic outcome of the primary causal variants,
called genetic modifiers [11]. Genetic modifiers contribute towards phenotypic variability
and penetrance and are thus important in precise diagnostic, prognostic, therapeutic
and overall patient management strategies [12]. Such variants or genetic modifiers are
being increasingly observed in neurodevelopmental disorders [13–16] but they have been
rarely reported for microcephaly and associated syndromes [17]. Interestingly, they have a
pronounced appreciation in mouse models of microcephaly [18,19].
The application of massively parallel sequencing of multiplex families offers a unique
opportunity to identify the modifying variants in a similar genetic background. Here, we
propose that heterozygous variants of WDR62, CEP63, RAD50 and PCNT contribute to
additional neurological and extra-neurological abnormalities in affected siblings of the
families manifesting MCPH or Seckel syndrome.
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2. Materials and Methods
2.1. Clinical Manifestations
We performed deep phenotyping and genotyping of five Pakistani multiplex families
presenting 28 patients segregating MCPH (three families) or Seckel syndrome (two families)
(Table 1, Figure 1A,B). We recruited these families from different areas of Punjab, Pakistan,
with prior written consents from the parents of all the families.
In each MCPH family, we noted microcephaly of varying degree (−9 to −15 SD),
slopping forehead and articulation difficulties (Figure 1B and Table 1). Intriguingly, some
of the kins showed additional phenotypic features, including joint contractures of both
elbows and hands, drooling, a short stature (family 1; V-1 and V-9), seizures, hyperactive
locomotion, dwarfism (family 2; V-1 and V-2), seizures, aggressive behavior and severe
forms of ID (family 3; IV-1 and IV-2) (Table 1 and Figure 1B). Similarly, patients of family
4 (V-6, V-7 and V-8) and 5 (IV-1 and IV-2) featured Seckel syndrome as indicated by a
beaky and protruding nose, hypopigmentation (family 4, V-7 only), malocclusion (family
5, IV-1 only) and short stature (Table 1 and Figure 1B), whereas other affected members
of family 4 (VI-2, VI-3 VI-4 and VI-5) also manifested mild ID, drooling, clinodactyly of
toes and brachydactyly of fingers and toes evincing MOPDII (Table 1 and Figure 1B). Two
patients of family 4, one from each loop, were subjected to radiographic analysis, which
indicated bilateral clinodactyly of the 4th and 5th toes only in patient VI-4, manifesting
the MOPDII phenotype, and it was absent in patient V-7, showing features of Seckel
syndrome (Figure 2).
2.2. Next-Generation Sequencing
To reveal the causative variants, we selected the affected siblings showing the most
severe phenotypic abnormalities for targeted sequencing of a microcephaly gene panel
(family 2: V-1, family 3: IV-1, family 4: V-6 and VI-2) or whole-exome sequencing (family
1: V-9 and family 5: IV-1). The complete list of genes included into the panel and the
process of targeted sequencing has been published elsewhere [10]. For whole-exome
sequencing (WES), we used the Agilent (Santa Clara, CA, USA) version 6 enrichment kit
and Illumina HiSeq 4000 sequencing system (paired end reads, 2 × 75bp). The detailed
procedure for WES has been described elsewhere [10]. Variant calling and interpretation
was performed with the help of our in-house VARBANK database and analysis platform
(http://varbank.ccg.uni-koeln.de (accessed on 9 May 2021)).
2.3. Linkage Analysis
For family 4, we genotyped the DNA of the four affected members (V-6, V-8, VI-
2 and VI-3), indicated by asterisks in Figure S1B, using the HumanCoreExome 24 v.1.1
BeadArray (Illumina; San Diego, CA, USA) according to the manufacturer’s instructions.
Linkage analysis was performed assuming autosomal recessive inheritance, full penetrance,
consanguinity and an allelic frequency of 0.0001. The procedure of data handling and
evaluation has been described earlier [20]. The detailed procedure of the statistical analysis
is given in Supplementary Materials. To fine-map the PCNT locus on chromosome 21, we
genotyped six neighboring microsatellite markers with the DNA of ten family members
(indicated by asterisks in Figure S1C). HaploPainter v.1.043 was used to construct the
haplotypes [21].
2.4. Sanger Sequencing
Co-segregation studies were performed by Sanger sequencing, including all family
members for which a DNA sample was available.
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Table 1. Clinical and molecular presentations of MCPH and Seckel syndrome families carrying mutations in the main genes that induce the phenotypes and the modifier genes that result
in the enhancement of the phenotypes.
(a)
Family 1 Family 2 Family 3
Patient ID VI-1 VI-2 VI-3 V-4 V-1 V-9 IV-1 V-1 V-2 IV-1 IV-2 IV-3
Gene 1
Gene name ASPM ASPM ASPM ASPM ASPM ASPM ASPM ASPM ASPM ASPM ASPM ASPM
Zygosity Homo Homo Homo Homo Homo Homo Homo Homo Homo Homo Homo Homo
cDNA mutation c.9601C>T c.9601C>T c.9601C>T c.9601C>T c.9601C>T c.9601C>T c.719_720delCT c.719_720delCT c.719_720delCT c.9492T>G c.9492T>G c.9492T>G
Protein mutation p.(Gln3201*) p.(Gln3201*) p.(Gln3201*) p.(Gln3201*) p.(Gln3201*) p.(Gln3201*) p.(Ser240Cysfs*16) p.(Ser240Cysfs*16) p.(Ser240Cysfs*16) p.(Tyr3164*) p.(Tyr3164*) p.(Tyr3164*)
Gene 2
Gene name - - - - WDR62 WDR62 - CEP63 CEP63 RAD50 RAD50 -
Zygosity - - - - Hetero Hetero - Hetero Hetero Hetero Hetero -
cDNA mutation - - - - c.3116A>G c.3116A>G - c.1241A>T c.1241A>T c.3643C>G c.3643C>G -
Protein mutation - - - - p.(Ser1106Gly) p.(Ser1106Gly) - p.(Thr421Ser) p.(Thr421Ser) p.(Leu1215Val) p.(Leu1215Val) -
Measurement
Age (years) 12 9 6 23 32 10 34 6 3 18 14 10
Gender Male Female Female Male Female Male Female Male Female Female Female Female
HC (cm) 41 35 34 42 41.5 37 35 37.5 32 41 43 38
HC (SD) −10 −14.55 −15 −10 −10 −12 −14.55 −11 −15 −10.5 −9 −13
Height (cm) 133 115 105 162 124 99 145 93 76 137 145 112
Height (SD) −2 −3 −2.5 −2 −7 −6 −3 −5 −5 −5 −3 −4
Neurological features
ID Moderate Mild Severe Moderate Severe Mild Moderate Moderate Moderate Severe Severe Mild
Behavior Aggressive Aggressive Aggressive Aggressive Aggressive Aggressive Aggressive Aggressive Aggressive Aggressive Aggressive Normal
Speech
impairment Severe Severe Severe Severe Severe Severe Severe Moderate Severe Mild Mild Mild
Musculoskeletal abnormalities
Contractures - - - - Joints (elbowand hands)
Joints (elbow
and hands) - - - - - -
Clinodactyly of
toes - - - - - - - - - - - -
Clinodactyly of
fingers - - - - - - - - - - - -
Brachydactyly of
fingers - - - - - - - - - - - -
Brachydactyly of
toes - - - - - - - - - - - -
Others
Drooling - - - - Yes Yes - - - - - -
Locomotion Normal Normal Normal Normal Normal Normal Normal Hyperactive Hyperactive Normal Normal Normal
Seizures - - - - - - - Yes Yes Yes Yes -
Hypopigmentation - - - - - - - - - - - -
Teeth Normal Normal Normal Normal Normal Normal Normal Normal Normal Normal Normal Normal
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Table 1. Cont.
(b)
Family 4 Family 5
Patient ID V-6 V-7 V-8 VI-2 VI-3 VI-4 IV-1 IV-2
Gene 1
Gene name CENPJ CENPJ CENPJ CENPJ CENPJ CENPJ CENPJ CENPJ
Zygosity Homo Homo Homo Homo Homo Homo Homo Homo
cDNA mutation c.3586G>A c.3586G>A c.3586G>A c.3586G>A c.3586G>A c.3586G>A c.3586G>A c.3586G>A























Gene name - - - PCNT PCNT PCNT - -
Zygosity - - - Hetero Hetero Hetero - -
cDNA mutation - - - c.5767C>T c.5767C>T c.5767C>T - -
Protein mutation - - - p.(Arg1923*) p.(Arg1923*) p.(Arg1923*) - -
Measurement
Age (years) 32 22 20 8 6 4 10 4
Gender Female Male Female Male Male Female Male Male
HC (cm) 44 47 45 39 35 35 35 35
HC (SD) −8.5 −7 −7.5 −10 −13 −11.5 −12 −11
Height (cm) 139 156 145 107 91 86 114 81
Height (SD) −4.5 −4 −4 −4 −5 −4 −4 −5
Neurological features
ID Moderate Moderate Moderate Mild Mild Mild Moderate Moderate
Behavior - - - - - - Normal Aggressive
Speech
impairment Severe Moderate Mild Moderate Severe Moderate Moderate Moderate
Musculoskeletal abnormalities
Contractures - - - - - - - -
Clinodactyly of
toes - - - Yes (bilateral) Yes (bilateral) Yes (bilateral) - -
Clinodactyly of
fingers - - - - - - - -
Brachydactyly of
fingers - - - Yes (bilateral) Yes (bilateral) Yes (bilateral) - -
Brachydactyly of
toes - - - Yes (bilateral) Yes (bilateral) Yes (bilateral) - -
Others
Drooling - - - Yes Yes Yes Very rare -
Locomotion Normal Normal Normal Normal Normal Normal Normal Normal
Seizures - - - - - - Very rare Normal
Hypopigmentation Yes (forehead) Yes (forehead) - - - - - -
Teeth Normal Normal Normal Normal Normal Normal Malocclusion Normal
Note: “-” means absence of the feature; NR, No Record; HC, Head Circumference; ID, Intellectual Disability; cm, Centimeter; SD, Standard Deviation. Second mutation of CENPJ shown in family 4 and 5 is based
on RT-PCR data, which revealed a second transcript lacking 78 bp (c.3541_3618del) of CENPJ and resulting in an in-frame deletion of 26 amino acids, p.(Val1181_Val1206del).
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Figure 1. Pedigrees and clinical features of patients. (A) Pedigrees of families manifesting primary
microcephaly and Seckel syndrome carrying homozygous loss-of-function mutations in ASPM and
CENPJ (shown in black beneath symbols), respectively, and heterozygous mutations in the proposed
modifier genes (shown in red above the symbols). Affected members of family 5 were found mutated
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1. Family 4 (V-6, V-7 and V-8) and family 5 feature Seckel syndrome whereas patients in the left
loop of family 4 (VI-2, VI-3, VI-3 and VI-5) are clinically diagnosed with MOPDII. White arrowheads
shown on the forehead areas of V-6 and V-7 of family 4 indicate hypopigmentation.
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4th and 5th toes is seen only in MOPDII patients, indicated by white arrow heads.
2.5. In Silico Analyses of Identified Variants
Pathogenicity of the identified variants were predicted by several in silico tools like
the ACMG classification system, Mutation Taster, Provean, Polyphen-2, CADD, PANTHER
(Paul Thomas, CA, USA), PhD-SNP (Bologna Biocomputing Group, Bologna, Italy), SIFT
(Pauline Ng, Genome Institute of Singapore, Singapore), SNAP (Yana Bromberg, University
of Columbia, Columbia, NY, USA), Meta SNP (Emidio Capriotti, University of Alabama at
Birmingham, Bir ingham, AL, USA/Yana Bromberg, Rutgers University, New Brunswick,
NJ, USA), MuPro (University of C lifornia, Irvine, CA, USA), SNPs&GO (Rita Casadio
and Emidio Capriotti, University of Bologna, Italy) and MetaDome (Christian Gilissen,
Radboud University Medical Center, Nijmegen, The Netherlands). To investigate the
conservation status of the mutated sites, reference sequences were retrieved either from
UniProtKB (https://www.uniprot.org/, (accessed on 9 May 2021)) or NCBI (https://
www.ncbi.nlm.nih.gov/ (accessed on 9 May 2021)) and were aligned by Clustal Omega
(EMBL-EBI, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK).
2.6. Reverse Transcription PCR
To explore the possible consequences of the CENPJ missense variant on splicing accuracy,
RNA was extracted from the patien ’s blood using the PAXgen bl od RNA system (QIAGEN,
Hilden, Germany) and subsequently converted to cDNA as described previously [22]. In brief,
RT-PCR was performed using forward 5′-AGCCACTTGAACCACTGAAC-3′ and reverse
5′-CAGTCTGGTCAGGAAACGTG-3′ primers to amplify the relevant portion of CENPJ.
Amplicons were resolved on a 2% agarose gel along with a 1 kb plus DNA ladder (10787018,
Thermo Fisher Scientific, Waltham, MA, USA) as the size marker. Each band was Sanger
sequenced separately to determine the effects on splicing.
2.7. Immunocytochemistry
To investigate the effects of the CENPJ missense variant identified in families 4 and 5,
primary dermal fibroblasts were cultured from skin biopsies obtained from the affected
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individuals (V-8 and VI-2) of family 4, as described elsewhere [23]. For immunofluores-
cence, primary fibroblasts were grown on 12 mm coverslips with a maximum confluency
of 70%. The fixation of cells was performed using ice-cold methanol for 10 min at −20 ◦C.
After 10 min, cells were incubated with PBS (1×) followed by the blocking buffer PBG
(solution composition reported previously [20]) for 15 min. For immunofluorescence,
primary antibodies—mouse anti-CENPJ, 1:25 [24], and rabbit anti PCNT, 1:1000 (Abcam,
ab4448)—were applied to the cells and incubated at 4 ◦C overnight. Alexa Fluor 488 donkey
anti-mouse IgG (Invitrogen, A21202) and Alexa Fluor 568 goat anti-rabbit IgG (Invitro-
gen, A11011) were used as secondary antibodies, each at a dilution of 1:1000, along with
4′,6-diamidin-2′-phenylindol (DAPI) (MilliporeSigma, Saint Louis, MO, USA, D9564) for
staining of DNA. The slides were observed under a confocal microscope (Leica Microsys-
tems, Wetzlar Germany, LSM TCS SP5) to capture images.
2.8. Immunoblotting
For immunoblotting, cultured cells from the patients and a control were lysed in lysis
buffer (50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 0.5% Na-deoxycholate,
0.1% SDS) supplemented with a proteinase-inhibitor cocktail (MilliporeSigma, Saint Louis,
MO, USA, P8340). After denaturing the samples at 95 ◦C for 8 min in SDS sample buffer, the
proteins were finally resolved in 10% SDS-PAGE and blotted onto nitrocellulose membrane
(PROTRAN, Sigma Aldrich, Germany). The membrane was incubated overnight at 4 ◦C
with Rabbit anti CPAP, 1:500 (Proteintech Group, Inc, Rosemont, IL, USA, 11517-1-AP)
as primary antibody along with rat anti α-tubulin (Y/L1/2) [25], at a dilution ratio of
1:5 for the loading control. Secondary antibodies, anti-rabbit IgG peroxidase conjugate
(MilliporeSigma, Saint Louis, MO, USA, A6154) and anti-rat IgG peroxidase conjugate
(MilliporeSigma, Saint Louis, MO, USA, A5795) were applied at a dilution ration of 1:10,000,
followed by developing the blots using an enhanced chemiluminescence system.
3. Results
Family 1 is a very large consanguineous family with eight affected members having
microcephaly of −10 to −15 SD accompanied by mild to severe ID (Figure 1A,B and
Table 1). Sequencing data analysis of family 1 revealed a nonsense mutation, NM_018136.
4:c. 9601C>T; p.(Gln3201*), of ASPM (Table 1). A CADD score of 41 was obtained for
this variant and it was placed in the category of pathogenic variants (PVS1, PM2, PP3)
by the ACMG classification system. We found it neither in gnomAD nor in dbSNP build
153 (Table 2). This variant was segregating, as expected, a recessive inheritance pattern
(Figure 1A and Figure S2). Additional phenotypic presentation of the contracted joints,
drooling and short stature, which were observed only in a few affected members of this
family, prompted us to look for additional potentially disease-causing variants. As a result,
we found a heterozygous missense variant, NM_001083961.1:c.3316A>G;p.(Ser1106Gly), of
WDR62 (Table 1). Interestingly, this variant is not catalogued in Iranome and the Greater
Middle Eastern Variome. It is, however, present in gnomAD (with two heterozygous alleles)
and dbSNP build 153 (rs1389367700) (Table 2). Based on this ultralow allele frequency,
we investigated this variant further. Sanger sequencing revealed that this variant was
found only in patients showing additional features of joint contractures, short stature and
drooling (Figure 1A and Figure S2, Table 1). The variant p.(Ser1106Gly) does not reside in
any of the 15 WD repeats of WDR62 yet shows its deleterious nature by PhD-SNP, SIFT,
SNAP, Meta SNP and MuPro (Table 2). According to the ACMG classification system, it
is considered as a variant of uncertain significance (VUS). This position is not conserved
in mammals in general (Figure S3A); however, it is strictly conserved among primates
(Figure S3B). Notably, this variant could be detrimental and impair the function of WDR62
because Ser1106 is reported to be phosphorylated during mitosis [26].
Genes 2021, 12, 731 9 of 18
Table 2. Pathogenicity chart of the mutations identified in Pakistani families.
(a)








ASPM NM_018136.4 23 c.9601C>T p.(Gln3201*) Pathogenic(PVS1, PM2, PP3) - 41
Disease causing
(6.0) NA




0.0000325 19.21 Polymorphism(56) Benign (0.09)
Fam. 2
ASPM NM_018136.4 3 c.719_720delCT p.(Ser240Cysfs*16) NA 0.0000325 - Disease causing NA









ASPM NM_018136.4 23 c.9492T>G p.(Tyr3164*) Pathogenic(PVS1, PM2, PP5) - 35
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(6.0) NA
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PCNT NA NA NA NA NA NA NA NA NA
















Note: (a) † This particular cDNA mutation (78 bp deletion) resulted due to aberrant splicing examined by RT-PCT. †† Protein mutation due to a 78 bp in-frame deletion. Allele frequency shown in the column of
gnomAD was based on two heterozygous alleles in WDR62, one allele of ASPM and two heterozygous alleles of PCNT. Numbers shown in brackets below the prediction statuses indicate the pathogenicity scores
suggested by each tool. Mutations of ASPM and CENPJ are in homozygous forms whereas WDR62, CEP63, RAD50 and PCNT are in heterozygous states. Value reported under each prediction: PANTHER,
PhD-SNP, SNAP and Meta-SNAP (scale is 0 to 1 and more than 0.5 score signifies disease causing); SIFT (positive values: more than 0.5 score shows neutral effects of mutation); and MuPro (a score less than
0 means the mutation decreases the protein stability. NA means data not available. (b) † This particular cDNA mutation (78 bp deletion) resulted due to aberrant splicing examined by RT-PCT. †† Protein
mutation due to a 78 bp in-frame deletion. Mutations of ASPM and CENPJ are in homozygous forms whereas WDR62, CEP63, RAD50 and PCNT are in heterozygous states. Allele frequencies shown in the
column of gnomAD were based on two heterozygous alleles in WDR62, one allele of ASPM and two heterozygous alleles of PCNT. Numbers shown in brackets below the prediction statuses indicate the
pathogenicity scores suggested by each tool. Interpretation of values for PANTHER, PhD-SNP, SNAP and Meta-SNAP, scale is 0 to 1 and more than 0.5 score signifies disease causing; SIFT, positive values: more
than 0.5 score shows neutral effects of mutation; and MuPro, a score less than 0 means the mutation decreases the protein stability. NA means data not available.
Genes 2021, 12, 731 11 of 18
Family 2 is a five-generation consanguineous family with five affected members,
two of them deceased for unknown reason, manifesting microcephaly of −11 to −15 SD,
moderate ID and aggressive behavior (Figure 1A,B and Table 1). Sequence data analysis of
this family revealed a frameshift variant, NM_018136. 4:c.719_720delCT;p.(Ser240Cysfs*16),
in ASPM. As presumed, all the tested patients were homozygous for this variant (Figure
1A and Figure S2, Table 1). Because clinical manifestation of the proband subjected to gene
panel sequencing was severe (Table 1), the possibility of additional variants was explored.
We found a missense variant, NM_025180. 3:c.1261A>T;p.(Thr421Ser), of CEP63 that was
subsequently confirmed in his younger sister (V-2), manifesting a similarly severe clinical
presentation (Figure 1A and Table 1). Their asymptomatic brother (V-3) was a heterozygous
carrier of both the aforementioned variants in ASPM and CEP63. The CEP63 variant was
inherited from their asymptomatic father (IV-6), whereas the mother was homozygous
for the wild-type allele (Figure 1A and Figure S2). Interestingly, investigation of a second
loop of the same family showed absence of the CEP63 variant in affected (IV-1) as well
as in phenotypically normal members (IV-3 and IV-4), even though their mother was
heterozygous for this variant (Figure 1A). The variant was predicted to be disease-causing,
deleterious and probably damaging, and decreasing the protein stability by the in silico
tools Mutation Taster (score = 58), Provean (score = −2.830), Polyphen-2 (score = 1.000)
and MuPro (DDG = −0.54948253), respectively; however, it was classified as VUS (PM2,
BP1) by the ACMG classification system (Table 2). The pathogenic potential of this variant
was further strengthened by its absence in databases of genomic variants like gnomAD,
GME variome, Iranome and dbSNP build 153 (Table 1). Furthermore, multiple alignments
of Cep63 peptides, spanning the mutant residue, revealed that threonine at position 421 of
the human protein is highly conserved throughout the vertebrate lineage (Figure S3C).
Family 3 is consanguineous, having three affected female siblings showing HC of
-9 to −13 SD with phenotypic variability in the manifestation of seizures, ID and be-
havior (Figure 1A,B and Table 1). Variant filtration identified a nonsense mutation,
NM_018136.4:c.9492T>G;p.(Tyr3164*), of ASPM, homozygous in all affected members
(Figure 1A and Figure S2, Table 1). Two affected members (IV-1 and IV-2) of this family
presented severe ID accompanied by aggressive behavior compared to their younger sister
(IV-3), who showed mild ID and normal behavior (Table 1). Considering the heterogeneity
of the clinical features, we extended the search for additional disease-causing variant(s)
in other genes. To this end, we identified a heterozygous missense variant, NM_005732.
3:c.3643C>G;p.(Leu1215Val), of RAD50 inherited from their asymptomatic mother (III-2)
(Figure 1A and Figure S2). This variant is not listed in any of the aforementioned public
databases of genomic variations and is predicted to be pathogenic by Mutation Taster,
Polphen-2, PANTHER, PhD-SNP, SIFT, SNAP, Meta SNP, MuPro, MetaDome and CADD
(score = 23.5), albeit likely benign (PM1, PM2, BP1, BP4) by the ACMG (Table 2). We con-
sidered it a potential modifier because this variant was only carried by affected members
with severe phenotypic manifestations, IV-1 and IV-2, whereas the affected member IV-3
with a milder phenotype did not carry this variant (Figure 1A,B). Furthermore, the mu-
tated residue is highly conserved within a large group of organisms, including vertebrates,
insects, plants and even yeast—only worms contain leucine at this position (Figure S3D).
Family 4 is a multigenerational family with nine affected members born to two con-
sanguineous couples and exhibiting major phenotypic differences among patients of both
loops (Figure 1A,B). Affected siblings in loop 1 (right side) showed typical features of
Seckel syndrome whereas those of loop 2 (left side) showed more severe clinical features
reminiscent of MOPDII (Figure 1A,B and Table 1). Affected members of loop 1 showed
moderate ID, HC of −7 to −8.5 SD, short stature and protruding noses. In addition, two of
the three affected individuals of loop 1 showed hypopigmentation (Table 1 and Figure 1B,
white arrowheads). Affected members of loop 2 showed microcephaly of HC −10 to
−13 SD, short stature, mild ID, excessive drooling, speech impairment, clinodactyly of
only toes and brachydactyly of both fingers and toes (Figures 1B and 2, Table 1), suggest-
ing a different cause or that a genetic modifier might confer additional features. Gene
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panel sequencing of two patients, one of each loop, demonstrated a novel homozygous
CENPJ variant (NM_018451.4:c.3586G>A;p.(Asp1196Asn)) in both patients that were later
confirmed in all affected siblings of both loops by Sanger sequencing (Figure 1A and
Figure S2). The involvement of the missense variant of CENPJ in the disease etiology was
further corroborated by linkage analysis that highlighted a region on chromosome 13 with
a maximum LOD score of 4.3 (Figure S1A). The homozygous segment of 2.63 Mb was
flanked by the markers rs7981441 (24,075,006bp; GRCh38.p12) and rs9551309 (26,712,326bp;
GRCh38.p12), thus harboring CENPJ (Figure S1B).
Screening for additional variants revealed a previously reported heterozygous non-
sense variant of PCNT (NM_006031.5;c.5767C>T;p.Arg1923*) in the patients of loop 2,
suggesting a modifier role for PCNT (Figure 1A and Figure S2, and Table 2). Sanger se-
quencing demonstrated that the PCNT variant was inherited from the mother (V-2) and
carried by all the affected members of this loop, whereas this variant was absent from
all individuals of loop 1 (Figure 1A). Additionally, genotyping of microsatellite markers
in selected family members revealed that the PCNT variant haplotype (colored in red,
Figure S1C) was introduced by the unrelated male individual IV-2 and absent from all
tested family members of loop 1. The PCNT variant obtained a very high CADD score
of 42 and was predicted to be pathogenic (PVS1, PM2, PP3, PP5) by ACMG criteria and
disease-causing by Mutation Taster (Table 2).
We considered the missense mutation, NM_018451.4:c.3586G>A;p.(Asp1196Asn), of
CENPJ causative of Seckel syndrome in family 4 because it was not recorded in any of
the genomic variation databases and predicted to be pathogenic with a CADD score of
28.1, likely pathogenic (PM1, PM2, PP3, PP5) by the ACMG classification system and
disease-causing by Mutation Taster, PROVEAN, Polphen-2, PhD-SNP, SIFT, SNAP, Meta
SNP, MuPro and MetaDome (Table 2). Furthermore, the amino acid position 1196 of CENP-
J is strictly conserved from fungi to vertebrates, advocating for an indispensable role of this
aspartic acid residue (Figure S3E). RT-PCR analysis of a fragment spanning the variant and
neighboring exons using patient and control mRNA revealed that the presumable missense
mutation c.3586G>A (p.(Asp1196Asn)) of CENPJ at least partially also results in aberrant
splicing by activating a cryptic splice donor site located within exon 14. We noted two
bands of reduced intensity as compared to the single band of expected size (372 bp) seen
in the control (Figure 3A). One band of the mutant sample was of the same size as that of
the control while the second band was considerably smaller (~294 bp) (Figure 3A). Sanger
sequencing of the wild-type PCR product resulted in the expected transcript sequence
ranging from exon 13 to exon 16 (Figure 3B,C, upper panels). Sequencing of the upper mu-
tant band revealed an identical sequence with the only exception of the mutant nucleotide
c.3586G>A (Figure 2, lower left panel). Sequencing of the lower band, however, revealed
an in-frame deletion of 78 bp (c.3541_3618del) covering the 3′ region of exon 14 (Figure 3B,
lower right panel and Figure 3C, lower panel). Evidently, the mutation c.3586G>A of
CENPJ results in two different transcripts that are nearly equally represented, a full-length
one encoding a peptide with only one altered amino acid, p.(Asp1196Asn), and a shorter
one that encodes a peptide which lacks 26 amino acids, p.(Val1181_Val1206del).
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Figure 3. Investigation of CENPJ transcript and protein in family 4. (A) Electropherogram (2% aga-
rose) of amplicons covering portion of CENPJ obtained from cDNA of patient VI-2 of family 4 along 
with the wild type. (B) Schematic of partial region of CENPJ wild-type transcript (top) showing the 
locations of the primers (black arrows) used to amplify the cDNA. Lower left panel shows the sche-
matic of CENPJ transcript with a size comparable to that of the wild type and carrying the missense 
mutation. Lower right panel indicates the schematic of the mis-spliced transcript, with a 78-bp de-
letion (shown by zigzag lines) in exon 14. (C) Sanger traces of the amplicons obtained from mutant 
and wild-type cDNA. The top panel shows traces of the wild type and the lower panel belongs to 
the smaller, mis-spliced mutant, showing deletion of 78 bp. The position of the cryptic splice donor 
site (GT) is underlined in wild-type traces. (D) Confocal microscopy images of the primary fibro-
blasts derived from different patients (V-8 and VI-2) of family 4. Localization of CENP-J is indicated 
by white arrows (wild type) and arrowheads (mutants). Reduced immunoreactivity is evident in 
both mutants as compared to the wild type. Scale bar 5µm. (E) Immunoblotting showing the relative 
quantity of CENP-J (upper panel) in wild-type and patient-derived primary fibroblasts. The internal 
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region of CENPJ wild-type transcript (top) showing the locations of the primers (black arrows) used to amplify the cDNA.
Lower left panel shows the schematic of CENPJ transcript with a size comparable to that of the wild type and carrying the
missense mutation. Lower right panel indicates the schematic of the mis-spliced transcript, with a 78-bp deletion (shown
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primary fibroblasts derived from different patients (V-8 and VI-2) of family 4. Localization of CENP-J is indicated by white
arrows (wild type) and arrowheads (mutants). Reduced immunoreactivity is evident in both mutants as compared to the
wild type. Scale bar 5 µm. (E) Immunoblotting showing the relative quantity of CENP-J (upper panel) in wild-type and
patient-derived primary fibroblasts. The internal control α-tubulin is shown in the lower panel. (F) Percentage cells with
supernumerary centrosomes in wild-type and patient-derived primary fibroblasts of family 4. Exact data points are shown
on the top left side of the respective bar. Error bars depict the standard deviation (SD). The p values are 0.0003 for mutant
V-8 and 0.0001 for mutant VI-2 (Student’s t test); three experiments were considered where 100 cells were accounted for
each experiment.
These data intrigued us to follow the consequences of mutant CENP-J at the cellular
level. Immunofluorescence analysis in primary fibroblasts of wild-type origin revealed
bright staining of CENP-J at the centrosome, which is marked by pericentrin (Figure 3D,
white arrow). Contrarily, primary fibroblasts derived from two different patients of family
4—one carrying only the CENPJ mutation (V-8) and another carrying the CENPJ and the
PCNT mutation (VI-2)—showed faint staining of CENP-J, marked by white arrow heads
(Figure 3D). These findings were corroborated by immunoblotting where protein lysates
of the patient-derived primary fibroblasts showed faint immunoreactivity of CENP-J as
compared to the wild type (Figure 3E, upper panel, and Figure S4). Equal concentrations
of lysates were loaded as evident by the immunoreactivity of α-tubulin (Figure 3E, lower
panel, and Figure S4). In addition to the compromised stability of CENP-J, we also ob-
served a significant number of patient interphase cells with supernumerary centrosomes
(Figure 3D). On average, 7.33% of cells derived from the patient carrying only the CENPJ
mutation showed supernumerary centrosomes, whereas more than twice as many (15.66%)
of the cells derived from the patient carrying both mutations showed them (Figure 3F).
Notably, only 1.66% of the wild-type cells showed extra centrosomes (Figure 3F). Based
on this data, we speculate that the PCNT variant exacerbates cellular anomalies caused by
CENP-J dysfunction, consequently worsening the clinical phenotype in VI-2.
Family 5 is a consanguineous family with two affected male siblings showing typical
features of Seckel syndrome, such as a prominent nose, HC-11 to -12 SD and short stature
(Figure 1A,B and Table 1). Whole-exome sequencing, performed in one affected member,
revealed the same CENPJ missense variant (NM_018451.4:c.3586G>A;p.(Asp1196Asn))
that had been identified in family 4 (Figure 1A,B and Figure S2, Tables 1 and 2). The
identification of the same CENPJ variant in a second unrelated family with Seckel syndrome
provides strong evidence for its causal role in the disease etiology. Interestingly, exome
data analysis did not show any variation of PCNT in family 5.
4. Discussion
Here, we have provided evidence that heterozygous missense variants of WDR62,
CEP63 and RAD50 aggravate the phenotype of MCPH and a PCNT nonsense variant exacer-
bates the severity of Seckel syndrome features. Multiple lines of evidence advocate for their
potential to act as genetic modifiers; this includes absence of any record or report of the
rare alleles in the literature or databases of genomic variations, high pathogenicity scores as
calculated by several in silico tools, high conservation of the affected amino acid positions,
and last but not least, the known involvement of these genes in the neurodevelopmental
disorders, which are discussed below in a continuum of the respective modifiers.
The genes identified with modifier variants in this study have previously been found
dysfunctional in non-syndromic primary microcephaly and its syndromic forms. Mutations
in WDR62 were reported to cause primary microcephaly with or without severe brain
malformations (lissencephaly and pachygyria) [27,28]. A nonsense mutation in CEP63
was reported to cause Seckel syndrome in a Pakistani family, with three affected members
showing microcephaly and reduced height [29]. For this reason, short stature in our patients
could be explained by the combined effect of this heterozygous modifying variation of
CEP63 together with the homozygous 2 bp deletion in ASPM. Nonsense and frameshift
variants of RAD50 were previously reported in families afflicted with Nijmegen breakage
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syndrome-like disorder (MIM #613078). Patients with this disorder feature microcephaly,
ID, a characteristic ‘bird-like’ face and short stature [30]. Interestingly, mutations in PCNT
were found to be associated with MOPDII [8,31]. Notably, many of the encoded proteins
interact with each other and form a crucial complex necessary for centriole biogenesis;
e.g., Cep63, Asp homolog, also known as ASPM, and WDR62 recruit CENP-J at the site
of centriole biogenesis [7]. Therefore, it could be speculated that modifying variants may
affect the structure and/or function of the complex, thereby resulting in a more severe
phenotype. A critical role of the WDR62 mutation p.(Ser1106Gly), identified in family 1,
is highly convincing as Ser1106 has been reported to be a key site of phosphorylation in
mitosis [26]. Additionally, the conservation constraint on Ser1106 in primates could also
implicate that serine at this position might be subject to positive selection of this gene
attributing some primate-specific function.
hRAD50 is a well-known component of the hRAD50 MRN (Mre11, Rad50 and Nbs1)
complex with a well-established role in double-strand break (DSB) repair [32]. Our patients,
carrying a variation of RAD50, showed rare and irregular episodes of seizures, aggressive
behavior and severe ID. None of these features were observed in the affected sibling (IV-3)
who did not carry the RAD50 variation (Table 1). Furthermore, the variant p.(Leu1215Val)
resides within an Ala/Asp-rich domain (DA-box) highly conserved across vertebrates.
CENP-J mutation p.(Asp1196Asn) is located in its T complex protein 10 (TCP) domain
(residues 1159–1337), which interacts with STIL [33,34] and plays a crucial role during
centrosome biogenesis by mediating the tethering of pericentriolar material [34]. Another
mutation of CENPJ, NM_018451.4:c.3704A>T;p.(Glu1235Val), reported in a Pakistani MCPH
patient [35], lies close to our mutation and has been shown to impair this interaction, thus
inhibiting centriole biogenesis [33]. Therefore, we speculate that the mutation identified
by us may also impair the interaction with STIL and compromise the tethering ability of
CENP-J in general. Notably mutant CENP-J encoded by the second mutant transcript lacks
26 amino acids (p.(Val1181_Val1206del)), spanning a region of the TCP 10 domain and
could also show detrimental effects on the interaction with STIL. Furthermore, aspartic
acid at position 1196 is a highly conserved residue and, due to its negative charge, most
likely participates in protein/protein interaction.
Interestingly, homozygous pericentrin mutation p.Arg1923* was originally described
as a cause of MOPDII [8]. If the mutant protein would be formed by escaping from
nonsense mediated mRNA decay, it would result in a loss of two helical strands, loss of
nek2 interaction (residues 2983–3246) and loss of calmodulin-binding (residues 3195–3208),
which should result in severe consequences for the protein function in centrosome arrange-
ment. Therefore, we have seen severe centrosomal defects in cells carrying mutations in
CENPJ and PCNT. On a background of biallelic CENPJ mutations, haploinsufficiency of
PCNT may become overt and result in a more severe clinical picture, as seen in some of our
patients of family 4 (Figure 1B and Table 1).
To the best of our knowledge, there has been only one publication reporting the
contribution of a genetic modifier to the phenotype of MCPH. In addition to a homozygous
stop mutation in WDR62, NM_001083961.1:c.1605dupT;p.(Glu536*), originally reported
as c.1605_1606insT, the MCPH patient also carried a duplication of the chromosomal
segment 17q25-qter and a missense mutation, c.3361T>G;p.Phe1121Val, of TBCD on the
non-duplicated allele. More severe phenotypic manifestations were observed in this
patient as compared to one carrying only the homozygous WDR62 stop mutation [17],
which was attributed to the modifying effects of TBCD. In case of Seckel syndrome, only a
digenic inheritance pattern has been reported, with heterozygous mutations of CDK5RAP2
and CEP152 [36]. Another report showed apparently digenic triallelic inheritance in
patients manifesting MCPH, with the following combinations of genes: WDR62/CDK5RAP2,
ASPM/WDR62, and WDR62/CEP135. Unfortunately, the authors did not present any
data for the presumptive modifying effects of the additional variants on the phenotype.
Furthermore, they did not find any modifying effects of wdr62 or aspm ablations in zebrafish
upon knocking out casc5/knl1; merely, the quadriallelic ablation of wdr62 and aspm showed
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primary microcephaly in zebrafish [37]. Hence, these data lay a foundation for future
studies to investigate the modifying variants in MCPH cases. Importantly, the phenotypic
severity, corroborated by the sub-cellular anomalies confirmed by our experiments, models
an efficient strategy for future studies for validation of the modifying variants at the
functional level.
5. Conclusions
The data presented in our study are unique for the fact that our multiplex pedigrees
show intrafamilial phenotypic and genotypic differences, thus providing a solid basis
to investigate the role of potentially modifying variants. We have provided compelling
evidence of the pathogenic nature of these variants, yet further functional analyses will
provide deeper insights into the pathomechanisms involving more than one mutated gene.
Based on our data, we recommend clinicians and researchers to subject the DNA of the
most severely affected members of larger families to comprehensive genomic analyses,
which may help to identify supplementary disease-modifying gene variants in addition to
the disease-causing ones.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/genes12050731/s1, Figure S1: Linkage and haplotype analysis of family 4. (A) Genome-
wide LOD plot using markers equally spaced by 100 kb. The maximum LOD score of 4.3 was
reached on chr 13. The homozygous region covers the CENPJ locus. (B) Haplotypes generated
to show the homozygous region of approximately 2.63 Mb located at chromosome 13 harboring
CENPJ. The haplotype drawing is splitted into two panels. Left panel indicates the family mem-
bers belonging to second, third and fourth generations whereas individuals belonging to fifth
and sixth generations are shown in the right panel. Arrowheads show the recombinant markers,
rs7981441 (24,075,006 bp) and rs9551309 (26,712,326 bp). Physical positions refer to human genome
build GRCh38.p12. (C) Haplotypes constructed by genotyping microsatellite markers surround-
ing PCNT. Asterisks denote the affected members used for genotyping. The arrowhead pointing
between D21S1885 (chr21:44,759,989-44,960,367 bp) and D21S1446 (chr21:47,937,583-48,129,895 bp)
indicates the position of PCNT (47,743,976-47,865,682 bp). Physical positions refer to human genome
build GRCh37.p13. Figure S2: Sanger traces of the identified mutations are shown. For each
family, chromatograms of the homozygous disease-causing variations are shown on top, and be-
low are the traces of heterozygous modifying variations. Traces of ASPM;c.719_720delCT het-
erozygous mutant are shown in reverse orientation. Figure S3: Multiple alignments of short
peptide sequences of WDR62, Cep63, hRAD50 and CENP-J from different species. Sites of the
mutant residue are colored in red. (A) UniProtKB IDs of WDR62 from different organisms are
as follows, O43379_HUMAN, XP_009666581 (Ostrich), A0A4W2FHS7_BOBOX, Q3U3T8_MOUSE,
F6UN22_MONDO, A0A670J9V7_PODMU and F6NPK9_DANRE. (B) UniProtKB and NCBI refer-
ence sequences IDs of WDR62 from selected primates have the following IDs, F7CAC3_MACMU,
A0A2K5MJV0_CERAT, O43379_HUMAN, H2QG55_PANTR, G3QFQ3_GORGO, H2NYJ6_PONAB,
U3BAJ3_CALJA and XP_012630407. 1_MICMU. (C) UniProtKB IDs of Cep63 are Q96MT8_HUMAN,
Q5NVN6_PONAB, Q3UPP8_MOUSE, Q4KLY0_RAT, P0CB05_CHICK, B9V5F5_XENLA and Q6PGZ0_
DANRE. (D) UniProtKB and NCBI reference sequence IDs of hRAD50 are Q92878_HUMAN, P70388_
MOUSE, XP_007473506, 1_MONDO, Q5W4T6_CHICK, A0A1L8GXM0_XENLA, F8W411_DANRE,
O44199_CAEEL, Q9W252_DROME, Q9SL02_ARATH and P12753_YEAST. (E) UniProtKB IDs of
CENP-J are as follows, Q9HC77_HUMAN, E1BL95_BOVIN, Q569L8_MOUSE, E1C0R8_CHICK,
E7FCY1_DANRE, H2ZX87_LATCH, F7C9Z3_XENTR, A9V5C9_MONBE, A0A0L8G7N5_OCTBM,
A0A0L0HNY0_SPIPN and Q9VI72_DROME. Figure S4. Immunoblot showing the reduced amount
of CENP-J in both patients (VI-2 and V-8) compared to wild type. Supplementary material 1: Link-
age analysis.
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